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ORIGINAL ARTICLE
Temporal Trend of Age at Diagnosis in 
Hypertrophic Cardiomyopathy
An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
Marco Canepa , MD, PhD; Carlo Fumagalli, MD; Giacomo Tini , MD; Justin Vincent-Tompkins, MS;  
Sharlene M. Day , MD; Euan A. Ashley, MRCP, DPhil; Francesco Mazzarotto , PhD; James S. Ware, PhD, MRCP;  
Michelle Michels, MD, PhD; Daniel Jacoby, MD; Carolyn Y. Ho, MD; Iacopo Olivotto , MD; The SHaRe Investigators
BACKGROUND: Over the last 50 years, the epidemiology of hypertrophic cardiomyopathy (HCM) has changed because of 
increased awareness and availability of advanced diagnostic tools. We aim to describe the temporal trends in age, sex, and 
clinical characteristics at HCM diagnosis over >4 decades.
METHODS: We retrospectively analyzed records from the ongoing multinational Sarcomeric Human Cardiomyopathy Registry. 
Overall, 7286 patients with HCM diagnosed at an age ≥18 years between 1961 and 2019 were included in the analysis and 
divided into 3 eras of diagnosis (<2000, 2000–2010, >2010).
RESULTS: Age at diagnosis increased markedly over time (40±14 versus 47±15 versus 51±16 years, P<0.001), both in US 
and non-US sites, with a stable male-to-female ratio of about 3:2. Frequency of familial HCM declined over time (38.8% 
versus 34.3% versus 32.7%, P<0.001), as well as heart failure symptoms at presentation (New York Heart Association III/
IV: 18.1% versus 15.8% versus 12.6%, P<0.001). Left ventricular hypertrophy became less marked over time (maximum 
wall thickness: 20±6 versus 18±5 versus 17±5 mm, P<0.001), while prevalence of obstructive HCM was greater in recent 
cohorts (peak gradient >30 mm Hg: 31.9% versus 39.3% versus 39.0%, P=0.001). Consistent with decreasing phenotypic 
severity, yield of pathogenic/likely pathogenic variants at genetic testing decreased over time (57.7% versus 45.6% versus 
38.4%, P<0.001).
CONCLUSIONS: Evolving HCM populations include progressively greater representation of older patients with sporadic disease, 
mild phenotypes, and genotype-negative status. Such trend suggests a prominent role of imaging over genetic testing in 
promoting HCM diagnoses and urges efforts to understand genotype-negative disease eluding the classic monogenic paradigm.
Key Words: cardiomyopathy, hypertrophic ◼ genotype ◼ heart failure ◼ phenotype ◼ prevalence
Once considered a rare disease of the young, hypertrophic cardiomyopathy (HCM) is now rec-ognized as relatively common and increasingly 
diagnosed in middle-aged and older adults,1,2 bur-
dened by greater risk of developing atrial fibrillation 
and heart failure than sudden cardiac death.3,4 Older 
age at diagnosis in recent years pairs with the global 
aging of populations but also with greater HCM dis-
ease awareness and widespread use of cardiac imag-
ing, particularly echocardiography. Both have resulted 
in increasing rates of incidental diagnoses in other-
wise asymptomatic individuals.5,6 Advances in genetic 
testing may also have played a role, mostly by virtue of 
cascade family screening.7
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A comprehensive perception of this trend and its 
implications based on large multinational HCM popula-
tions may help shape future diagnostic and prognostic 
algorithms and allocate clinical and genetic resources.
We herein describe the temporal trends in age, 
sex, and clinical characteristics at HCM diagnosis 
in patients enrolled in the international Sarcomeric 
Human Cardiomyopathy Registry (SHaRe) over the 
last 4 decades.
METHODS
The SHaRe registry is an international database created by 
11 HCM centers, which comprises over 7000 patients.4 The 
registry conforms to the principles of the Helsinki declaration 
and the local institutional review boards approved the study 
protocol. All participants gave informed consents. The data 
will not be made available to other researchers for purposes of 
reproducing the results or replicating the procedure because 
of constraints related to human subjects research. Analytical 
methods will be made available on request. For this analysis, 
records were updated to the first quarter of 2019. We ret-
rospectively reviewed clinical records of all SHaRe HCM 
patients diagnosed at an age ≥18 years. Temporal trends in 
parameters of interest were plotted by quinquennial periods. 
In addition, clinical and instrumental data at diagnosis were 
stratified into 3 groups: patients diagnosed <2000, 2000 to 
2010, and >2010.
Age at HCM diagnosis was distinguished from age at initial 
site evaluation. HCM was defined by the presence of increased 
asymmetrical left ventricular (LV) wall thickness ≥13 mm in 
the absence of abnormal loading conditions.4 Genetic testing 
was performed at all sites using the platforms locally available 
over time. Variants in the sarcomeric genes were classified as 
pathogenic or likely pathogenic (SARC+), variant of unknown 
significance (SARC VUS), or no pathogenic variants (SARC−) 
by each site using contemporary criteria and through a subse-
quent standardization.4
Statistical Analysis
Data are expressed as percentages, mean and SD, or median 
with interquartile range for skewed distributions. Temporal 
trends in the main characteristics of patients at enrollment in 
the registry were analyzed using parametric tests (Student t 
test, or ANOVA when >2 input variable categories were pres-
ent) and nonparametric when necessary (for non-normal distri-
butions—Mann-Whitney U test or Kruskal-Wallis test when >2 
input variable categories were present) for continuous variables 
and the χ2 or Fisher exact test (if cell count was <5 in one 
of the cells) for categorical data. Statistical analysis was per-
formed with SPSS v24.0 (IBM, Armonk, NY).
RESULTS
Overall, 7286 patients with HCM, diagnosed between 
1961 and March 2019 at 6 US (n=3212) and 5 non-
US (n=4074) participating centers, were included in the 
analysis (Table). The number of HCM diagnoses was 
low before 2000 and increased significantly after 2000 
(35/y <2000 versus 272/y in 2000–2010 versus 357/y 
>2010), particularly in US sites. Patients were progres-
sively older at HCM diagnosis (40±14 versus 47±15 
versus 51±16 years in patients diagnosed <2000 ver-
sus 2000–2010 versus >2010 respectively, P<0.001), 
with a similar trend in US and non-US sites (Table, Figure 
[A]). Rate of diagnoses >60 years increased from 9.2% 
before 2000 to 31.8% after 2010. Notably, prevalence 
of patients diagnosed at >70 years reached 10.7% after 
2010 (Table). Male-to-female ratio remained stable at 
about 3:2 (Figure [B]). Starting in 1984, women were 
significantly older than men at diagnosis, with a mean 
age gap of 4.5±0.6 years (Figure [B]). The number of 
diagnoses in nonwhite individuals increased over time, 
as well as the prevalence of hypertension and obesity 
(Table). Most patients were first family member present-
ing for care at the site (ie, probands), without significant 
changes over time (Table).
Prevalence of patients with positive HCM family 
history declined during the study period (38.8% ver-
sus 34.3% versus 32.7%, P<0.001). Genetic testing 
was performed in 4496 patients (61.7% of the overall 
Nonstandard Abbreviations and Acronyms
HCM hypertrophic cardiomyopathy
LV left ventricular
SARC+  pathogenic or likely pathogenic variants 
of sarcomeric genes
SARC−  no pathogenic variants of sarcomeric 
genes
SHaRe  Sarcomeric Human Cardiomyopathy 
Registry
WHAT IS NEW?
• In this analysis from a large international registry, we 
observed how patients with hypertrophic cardiomy-
opathy, irrespective of the geographic region of ori-
gin, have become older at presentation in recent 
cohorts, often asymptomatic, with milder pheno-
types and a more frequently negative or inconclu-
sive genetic test.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Our findings likely reflect a greater physician aware-
ness and diagnostic sensitivity in the medical com-
munity. The increasing number of hypertrophic 
cardiomyopathy diagnoses in older patients with 
milder phenotype and sporadic disease will sig-
nificantly change the therapeutic and prognostic 
landscape of this condition and further questions 
its classic monogenic paradigm.
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population): SARC+ variants were identified in 2028 
(45.1%; Table). SARC− patients were diagnosed at 
an older age than those with SARC VUS or SARC+ 
throughout the whole study period (Figure [C]). The 
yield of genetic testing gradually declined with time, 
from 57.7% SARC+ before 2000 to 38.4% SARC+ 
after 2010, paralleled by a concomitant increase in 
SARC VUS (Table; Figure [C]).
Table. Baseline Characteristics of Patients Diagnosed With HCM in the SHaRE Registry Overall and by Year of Diagnosis
 
Overall Year of diagnosis
P ValueN=7286
<2000 2000–2010 >2010
N=1344 (18.4%) N=2724 (37.4%) N=3218 (43.5%)
Demographics
 HCM diagnoses per year 103 35 272 357  
 Diagnosis at US centers, n (%) 3212 (43.7) 467 (34.7) 1118 (41.0) 1627 (52.1) <0.001
 Diagnosis at non-US centers, n (%) 4074 (55.9) 877 (65.3) 1606 (59.0) 1591 (49.4)  
 Age at diagnosis, y 48±16 40±14 47±15 51±16 <0.001
 Age groups, n (%) <0.001
  <40 y 2386 (32.7) 705 (52.2) 887 (32.6) 794 (24.7)  
  40–60 y 3148 (43.1) 515 (38.3) 1233 (45.3) 1400 (43.5)  
  >60 y 1719 (24.0) 124 (9.2) 604 (22.2) 1024 (31.8)  
 Age >70 y, n (%) 561 (7.7) 30 (2.2) 186 (6.8) 345 (10.7) <0.001
 Age at diagnosis in US centers, y, n (%) 48±15 38±13 48±15 51±16 <0.001
 Age at diagnosis in non-US centers, y, n (%) 48±16 41±15 47±15 51±16 <0.001
 Family proband, n (%) 6637 (91.1) 1236 (92.0) 2473 (90.8) 2925 (90.9) 0.49
 Sex (men), n (%) 4332 (59.5) 821 (61.1) 1647 (60.5) 1864 (57.1) 0.06
 White race, n (%) 6152 (84.4) 1183 (88.0) 2321 (85.2) 2648 (82.3) 0.001
 Hypertension, n (%) 1333 (18.3) 265 (19.7) 572 (21.0) 743 (23.1) 0.032
 Obesity, n (%) 2332 (32.0) 384 (28.6) 872 (32.0) 1094 (34.0) 0.045
Clinical characteristics
 NYHA class, n (%)* <0.001
  I 2557 (49.5) 476 (42.3) 977 (49.8) 1104 (53.2)  
  II 1829 (35.4) 445 (39.6) 673 (34.3) 711 (34.3)  
  III 728 (14.1) 187 (16.6) 286 (14.6) 255 (12.3)  
  IV 47 (0.9) 17 (1.5) 24 (1.2) 6 (0.3)  
 Family history of HCM, n (%) 2513 (34.5) 522 (38.8) 938 (34.3) 1053 (32.7) <0.001
 Genetic testing available, n (%) 4496 (61.7) 892 (66.4) 1792 (65.8) 1812 (56.3)  
 Genetic testing results, n (%) <0.001
  SARC+ 2028 (45.1) 515 (57.7) 817 (45.6) 696 (38.4)  
  SARC VUS 379 (8.4) 66 (7.4) 136 (7.6) 177 (9.7)  
  SARC− 1984 (44.1) 294 (32.9) 810 (45.2) 880 (48.5)  
 ESC SCD risk score† 2.1 (1.4–3.1) 2.4 (1.7–3.5) 2.1 (1.5–3.1) 1.80 (1.3–2.9) <0.001
Echocardiographic characteristics
 LA diameter, mm 43±10 46±12 44±11 41±10 <0.001
 Max LVWT 18±5 20±6 18±5 17±5 <0.001
 LVEF 66±9 63±12 67±9 67±8 <0.001
 LVOT obstruction (peak gradient >30 mm Hg)‡ 1771 (37.7) 309 (31.9) 708 (39.3) 754 (39.0) 0.001
 Rest LVOT peak gradient 31±34 28±31 33±36 29±35 0.001
 Provocable LVOT peak gradient 48±43 40±37 50±42 49±44 0.005
Obesity identifies body mass index ≥30 kg/m2. ESC SCD indicates European Society of Cardiology Sudden Cardiac Death; HCM, hypertrophic cardiomyopathy; LA, 
left atrial; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; LVWT, left ventricular wall thickness; NYHA, New York Heart Association functional 
class; SARC+, pathogenic and likely pathogenic mutations; SARC−, no pathogenic mutations; SARC VUS, sarcomeric variant of unknown significance; and SHaRE, 
Sarcomeric Human Cardiomyopathy Registry.
*Available in 5161 patients.
†Calculated on 3904 patients.
‡Calculated on 4698 exams.
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Severity of heart failure symptoms at presentation 
declined after 2000 (New York Heart Association III/IV: 
18.1% versus 15.8% versus 12.6%, P<0.001), with pro-
gressive emergence of asymptomatic patients (Table). 
Maximal LV wall thickness at diagnosis significantly 
decreased over time (20±6 versus 18±5 versus 17±5 
mm, P<0.001), while obstructive HCM was progressively 
more prevalent (Table). Moreover, patients diagnosed 
after 2010 had smaller left atrial diameters and higher LV 
ejection fraction. This collective trend translated in a pro-
gressively lower estimated risk of sudden cardiac death 
at diagnosis, according to the 2014 European Society of 
Cardiology prediction model (Table).
DISCUSSION
The number of HCM diagnoses has steadily increased 
worldwide over the last 40 years, with dramatic change 
in the perception of the disease and its epidemiology 
(from rare/malignant to relatively common/relatively 
favorable). In this analysis from a large international reg-
istry, we observed how patients with HCM, irrespective 
of the geographic region of origin, have become older at 
presentation in recent cohorts, often asymptomatic, with 
milder phenotypes and a more frequently negative or 
inconclusive genetic test. A similar trend has been previ-
ously described in an Italian nationwide survey of 1677 
patients with HCM conducted in the year 2002.1 Spe-
cifically, age at HCM diagnosis was found to increase 
from an average of 36 years before 1982 to 44 years 
after 1992. Subsequent administrative US data have 
confirmed that the average age of patients with HCM 
known today falls in the fifth decade of life.2 In the 
SHaRe registry, mean age at HCM diagnosis after 2010 
was 51±16 years, and females were consistently older 
than male patients. These findings were paralleled by 
an evolving perception of the disease spectrum, moving 
from classic to atypical and less dramatic phenotypes. 
Patients in New York Heart Association functional class 
I, constituting 42.3% of the total SHaRe cohort before 
2000, peaked at >53% after 2010. This is in accordance 
with the seminal findings from the CARDIA study, where 
an unexpectedly high prevalence was found by echocar-
diographic population screening, revealing a majority of 
asymptomatic, undiagnosed HCM subjects in the com-
munity.8 The fact that more asymptomatic HCM individu-
als are identified in the clinical setting (as opposed to 
population screening initiatives) reflects greater physi-
cian awareness and diagnostic sensitivity.5
Our findings, combined with prior reports, stimulate 
a number of relevant epidemiological considerations. 
First, the contemporary size of known HCM populations 
are still far from the total number of patients expected 
based on national estimates of 1:500 to 1:3000 to 
3500 individuals.2 Even accounting for a consider-
able proportion of individuals not followed at academic 
centers—and therefore unreported in the literature—the 
ultimate, real-world profile of HCM is being progres-
sively uncovered but still not completely unraveled. Sec-
ond, the exponential increase in HCM diagnoses seems 
Figure. Temporal trends and distributions in age at hypertrophic cardiomyopathy diagnosis by site, sex, and genetic status.
SARC+ indicates pathogenic and likely pathogenic mutations; SARC−, no pathogenic mutations; and SARC VUS, sarcomeric variant of 
unknown significance.
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because of the systematic exploitation of electrocar-
diography and echocardiography, rather than to more 
advanced diagnostic tools.9,10 Indeed, the boom in HCM 
diagnoses occurred around the year 2000, with some 
limited increase after that date. Based on this simple 
temporal criterion, novel technologies such as cardiac 
magnetic resonance and next generation sequencing 
genetics thus seems to have contributed poorly to this 
epidemiological shift.11 Third, the number of diagnoses 
in the classical niche of HCM (young males with marked 
hypertrophy, familial disease, and SARC+ carriers) has 
remained substantially stable after the year 2010, and 
the multiplication in cohort size is increasingly due 
to the inclusion of older, genotype-negative patients 
with sporadic disease and less marked LV hypertro-
phy. The higher prevalence of the obstructive pheno-
type in recent cohorts seems to counter this general 
trend; however, LV obstruction has been described as 
a frequent feature of older, generally SARC−, patients 
with HCM12 and attributed to geometric and functional 
modifications of the left ventricular outflow tract in rela-
tion to age.3,13
Overall, characteristics at diagnosis of contemporary 
HCM cohorts significantly differ from the classic disease 
described in the 1960s and 1970s. Consistently, we 
observed a growing number of diagnoses in genotype-
negative HCM, as opposed to high gene testing yields in 
the early cohorts. Recently, there has been a call to arms 
to address this knowledge gap, and the classic HCM 
monogenic paradigm has been questioned.11 Our results 
embrace this view and force us to speculate regarding 
the pathogenic mechanisms on the basis of the increas-
ing cohort of SARC VUS carriers and genotype-negative 
patients, accounting for about 60% of HCM diagnoses 
after 2010 in the SHaRe registry population. The avail-
ability of more genes and variants in larger next generation 
sequencing panels has likely contributed to increasing the 
number of SARC VUS, but not SARC+ patients in later 
years. This does not question the seminal theory of HCM 
as a disease of the sarcomere—which has passed the 
test of time and has proven essential in developing novel, 
groundbreaking therapies.14 However, it is by now clear 
that beyond a typical HCM phenotype, lay diverse subsets 
of phenotypes which seems to escape a monogenic logic 
and involve other, still unknown, mechanisms. The epide-
miological picture emerging from the present suggests 
the need for additional efforts involving clinical and basic 
science, as well as the opportunity to re-think classic man-
ifestations of disease and their implications for screening 
strategies, risk stratification, and allocations of resource.
CONCLUSIONS
Rapidly expanding international HCM populations include 
progressively older patients, with sporadic disease, mild 
phenotypes, and genotype-negative status. This tempo-
ral trend suggests a driving role of imaging over genetic 
testing in enhancing HCM diagnoses and urges efforts 
to understand genotype-negative disease eluding the 
classic monogenic paradigm.
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